Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies

Journal of the National Cancer Institute

Volumn 88, Issue 24, 1996, Pages 1810-1820

  Salazar, Hernando ^b   Godwin, Andrew K ^a   Daly, Mary B ^a   Laub, Paul B ^a   Hogan, W Michael ^a   Rosenblum, Norman ^b   Boente, Matthew P ^a   Lynch, Henry T ^c   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BENIGN TUMOR; CANCER INVASION; CANCER RISK; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INHERITANCE; MALIGNANT NEOPLASTIC DISEASE; OVARIECTOMY; OVARY CANCER; PHENOTYPE; PROPHYLAXIS;

ADULT; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HUMANS; KERATINS; LINKAGE (GENETICS); MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PHENOTYPE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECANCEROUS CONDITIONS; RECEPTORS, ESTROGEN; RISK;

EID: 0030472570     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.24.1810     Document Type: Article

References (57)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. 1995. CA Cancer J Clin 1995;45:8-30.
2. van der Berg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer [see comment citations in Medline]. N Engl J Med 1995;332:629-34.
3. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
4. Scully R. Histological typing of female genital tract tumours. New York: Springer-Verlag, 1994.
5. Stalsberg H, Bjarnason O, de Carvalho A, Correa P. International comparison of histologic types of ovarian cancer in cancer registry material. UICC Tech Rep Ser 1983;75:247-80.
6. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994;73:1859-64.
7. Scully R. Ovary. In: Henson D, Albores-Saavedra J, editors. Pathology of incipient neoplasia. Philadelphia: Saunders, 1993:283-300.
8. Nicosia S, Nicosia R. Neoplasms of the ovarian mesothelium. In: Azar H, editor. Pathology of human neoplasms. New York: Raven Press, 1988:435-86.
9. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994;54:2778-84.
10. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
11. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972;27:751-68.
12. Fox H. Pathology of early malignant change in the ovary. Int J Gynecol Pathol 1993;12:153-5.
13. Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. Cancer 1993;71(2 Suppl):530-6.
14. Lowry S, Russell H, Hickey I, Atkinson R. Incessant ovulation and ovarian cancer [letter] \see comment citation in Medline]. Lancet 1991;337:1544-5.
15. Woodruff JD. History of ovarian neoplasia: facts and fancy. Obstet Gynecol Annu 1976;5:331-44.
16. Hamilton TC. Ovarian cancer. Part I: biology. Curr Probl Cancer 1992; 16:1-57.
17. Cramer DW, Xu H, Harlow BL. Does "incessant" ovulation increase risk for early menopause? Am J Obstet Gynecol 1995;172:568-73.
18. Scully R, Bell D, Abu-Jawdeh G. Update on early ovarian cancer and cancer developing in benign ovarian tumors. In: Sharp F, Mason P, Blackett T, et al, editors. Ovarian cancer 3. London: Chapman & Hall, 1995:139-44.
19. Ozols R, Rubin S, Dembo A, et al. Epithelial ovarian cancer. In: Hoskins W, Perez C, Young R, editors. Gynecologic oncology: principles and practice. Philadelphia: Lippincott, 1992:731-81.
20. Powell DE, Puls L, van Nagell J Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? [see comment citations in Medline]. Hum Pathol 1992;23:846-7.
21. Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
22. Cheng PC, Gosewehr JA, Kim T, Velicescu M, Wan M, Zheng J, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development [see comment citation in Medline]. J Natl Cancer Inst 1996;88:510-8.
23. Mittal KR, Zeleniuch-Jacquotte A, Cooper J, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63.
24. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors [see comment citation in Medline]. Obstet Gynecol 1993; 82:181-6.
25. Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996;58:42-51.
26. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
27. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996;58:1166-76.
28. Dawson-Saunders B, Trapp R. Basic and clinical biostatistics. Norwalk (CT): Appleton and Lange, 1994.
29. Armitage P. Statistical methods in medical research. New York: John Wiley & Sons, 1971.
30. Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995:173:97-104.
31. Hamilton T, Davies P, Griffiths K. Steroid-hormone receptor status of the normal and neoplastic ovarian surface germinal epithelium. In: Greenwald G, Terranova P, editors. Factors regulating ovarian function. New York: Raven Press, 1983:81-5.
32. Fearon ER. Vogelstein B. A genetic model for colorectal tumorgenesis. Cell 1990;61:759-67.
33. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-36.
34. Deligdisch L, Einstein AJ, Guera D, Gil J. Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer 1995;76:1027-34.
35. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, et al. Mutations in the BRCAI gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387-91.
36. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
37. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P. Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-97.
38. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
39. Hogervorst FB, Cornelis RS, Bout M, van Vliet M. Oosterwijk JC, Olmer R, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
40. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 1995;55:3521-4.
41. Johannsson O, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996;58:441-50.
42. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI. Science 1994;266:66-71.
43. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
44. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995;57:1-7.
45. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M. et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428-33.
46. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, et al. Growth retardation and tumour inhibition by BRCA1 [see comment citation in Medline]. Nat Genet 1996;12:298-302.
47. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R. Helou B, et al. BRCA1 is secreted and exhibits properties of a granin [see comment citations in Medline]. Nat Genet 1996;12:303-8.
48. Zheng J, Benedict W, Xu HJ, Hu SX, Kim TM, Velicescu M, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas [see comment citation in Medline]. J Natl Cancer Inst 1995;87:1146-53.
49. Gusberg SB, Deligdisch L. Ovarian dysplasia. A study of identical twins. Cancer 1984;54:1-4.
50. Graham J, Graham R, Scheuller E. Preclinical detection of ovarian cancer. Cancer 1964;17:1414-32.
51. Auersperg N, Maines-Bandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC. et al. Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol 1995;173:558-65.
52. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982;2:795-7.
53. Chen KT, Schooley JL, Flam MM. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 1985;66:93s-94s.
54. Lingeman CH. Environmental factors in the etiology of carcinoma of the human ovary: a review. Am J Ind Med 1983;4:365-79.
55. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer [see comment citation in Medline]. J Natl Cancer Inst 1992;84:592-601.
56. Godwin A, Hamilton T, Knudson A. Oncogenes and anti-oncogenes in gynecologic malignancies. In: Hoskins W, Perez C, Young R, editors. Gynecologic oncology: principles and practice. Philadelphia: Lippincott, 1992:87-116.
57. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH. Lynch HT, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996;12:309-11.